Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 15, 2023 | May 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 15, 2023 · Filed May 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,541 |
Ending reported balance
After 2023-05-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-15 · Grant · Acquired 664 · Balance 65,099 F1: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2023-05-15 · Grant · Acquired 442 · Balance 65,541 F2: The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $192.36 · Expires 2033-05-15 | Direct | 1,669 |
Reported balance
After 2023-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-15 · Grant · Acquired 1,669 · Balance 1,669 F3: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders.
F3: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2023 Filed May 17, 2023 14:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,669 | $192.36 Strike: $192.36 | $321,048.84 |
DisclosureSEC source: 0001127602-23-015854 · form4.xml · derivative · entry 3 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires 2033-05-15 F3 · shares: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 14:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 442 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015854 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,541 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 14:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015854 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,099 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,582 | $222.31 Strike: $222.31 | $351,694.42 |
DisclosureSEC source: 0001127602-22-014444 · form4.xml · derivative · entry 3 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582 Underlying: Common Stock · 1,582 shares Expires 2032-05-11 F3 · shares: The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 382 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014444 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,435 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 10, 2022. The restricted stock units vest upon the earlier of 5/11/2023, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014444 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,053 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 17:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $342.55 | $0.00 |
DisclosureSEC source: 0001127602-21-016115 · form4.xml · derivative · entry 3 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-07 F3 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 17:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016115 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,478 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2021, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 17:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016115 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,244 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 14:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-20-016240 · form4.xml · derivative · entry 3 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 F3 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 14:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 487 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016240 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,889 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 6, 2020. The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 14:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016240 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,402 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 23, 2019 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 619 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019736 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,661 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 21, 2019. The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 23, 2019 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019736 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,042 F1 · kind: Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2018 Filed May 15, 2018 16:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 699 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017515 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,160 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 8, 2018. The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2018 Filed May 15, 2018 16:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017515 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,461 F1 · kind: Consists of 2,004 unvested restricted stock units that vest upon the earlier of 5/14/2019, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,140 | $0.00 Strike: $70.29 | $0.00 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · derivative · entry 11 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,140 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,530 | $0.00 Strike: $52.29 | $0.00 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · derivative · entry 10 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,530 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,030 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · derivative · entry 9 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,030 shares Expires 2020-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,540 | $0.00 Strike: $33.93 | $0.00 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · derivative · entry 8 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,540 shares Expires 2019-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,740 | $0.00 Strike: $40.27 | $0.00 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · derivative · entry 7 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,740 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 10,227 | $102.40 | $1,047,244.80 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · nonDerivative · entry 6 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,457 Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,140 | $70.29 | $220,710.60 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · nonDerivative · entry 5 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,530 | $52.29 | $184,583.70 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · nonDerivative · entry 4 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,030 | $43.39 | $174,861.70 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · nonDerivative · entry 3 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,540 | $33.93 | $154,042.20 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 10:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 7,740 | $40.27 | $311,689.80 |
DisclosureSEC source: 0001127602-17-034175 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2017 Filed May 15, 2017 18:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 864 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018148 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,704 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 9, 2017, and includes an increase to the fee he receives for being Chair of the Compensation Committee fee, which was effective at the beginning of 2017. The restricted stock units vest upon the earlier of 5/12/2018, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 12, 2017 Filed May 15, 2017 18:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018148 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,840 F1 · kind: Consists of 2,436 unvested restricted stock units that vest upon the earlier of 5/12/2018, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 08:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,710 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001127602-16-068550 · form4.xml · derivative · entry 4 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,710 shares Expires 2017-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 08:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,988 | $71.93 | $286,856.84 |
DisclosureSEC source: 0001127602-16-068550 · form4.xml · nonDerivative · entry 3 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,404 Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 08:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 551 | $71.92 | $39,627.92 |
DisclosureSEC source: 0001127602-16-068550 · form4.xml · nonDerivative · entry 2 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,392 Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 08:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 10,710 | $30.44 | $326,012.40 |
DisclosureSEC source: 0001127602-16-068550 · form4.xml · nonDerivative · entry 1 REESE C RICHARD · CIK 0001032365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.